SOURCE: Leerink Swann & Coomlany

August 26, 2005 06:00 ET

Leerink Swann & Company Initiates Coverage of Sanofi- Aventis SA (NYSE: SNY) and (Paris: SAN)

BOSTON, MA -- (MARKET WIRE) -- August 26, 2005 -- Yesterday after the close, Senior Pharmaceuticals Analyst, Andrew Oh, initiated coverage of Sanofi-Aventis SA with a Market Perform rating. Despite projected double-digit near-term earnings growth (16% in 2005 and 12% in 2006) and two potential blockbuster launches (Acomplia and Exubera), he believes that the company is fairly valued at present given the major generic risks facing the company and the lack of pipeline visibility (plus regulatory risk around Acomplia and Exubera).

About Sanofi-Aventis SA

Sanofi-Aventis SA (NYSE: SNY) and (Paris: SAN) is the world's third largest pharmaceutical company. It focuses on developing agents for cardiovascular disease, thrombosis, oncology, metabolic disease, the central nervous system, internal medicine and vaccines. Sanofi-Aventis is headquartered in Paris.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564